Stay updated with breaking news from Ib Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
INSIDE INFORMATION Combination of ATO with copper salts will allow BioSenic to work towards reducing the dosage of ATO in future trials overall and maintain efficacy Mont-Saint-Guibert,... | March 30, 2023
Mont-Saint-Guibert, Belgium, February 14, 2023, 5:45 pm CET – BioSenic , the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today... | February 14, 2023
REGULATED INFORMATION Mont-Saint-Guibert, Belgium, January 27, 2023, 7am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company...
REGULATED INFORMATION The autoimmune disease platform has completed a successful phase IIb trial targeting cGVHD (chronic Graft vs Host Disease), with a...
Press ReleaseMedia Contacts:IB CommunicationsTel +44 (0)20 89434685immutep@ibcomms.agency Immutep receives AUD 2.7 million research and development tax incentive from French government Sydney, Australia, September 23, 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the...